Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,763.96
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
102.48
(
-1.87%
)
Bitcoin
70,278.58
(
0.55%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 45571

Monday, 04/23/2007 3:08:39 AM

Monday, April 23, 2007 3:08:39 AM

Post# of 257262
QLTI’s CEO must be a ‘half-full’ kind of guy:

http://yahoo.reuters.com/news/articlehybrid.aspx?storyID=urn:newsml:reuters.com:20070423:MTFH92823_2...

>>
Visudyne sales in the United States for the quarter were about $8.4 million…

“Sales of Visudyne in the U.S. appear to have stabilized in January and grew in February and March due to increases in market share of combination therapy,” Chief Executive Bob Butchofsky said.
<<

Stabilized, perhaps, but utterly irrelevant to the future of AMD treatment.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now